Vox reports that recent policy shifts have led to confusion and uncertainty at the US Food and Drug Administration.
The Wall Street Journal reports that Rep. Tom Price, the pick to lead the Department of Health and Human Services, bought stock in a pharma firm at a special price.
The US immigration ban is already having an effect on US science, the New Scientist says.
Stat News writes that the new executive order on government regulations could affect the 21st Century Cures Act.
Stat News reports that Joseph Gulfo is another contender for FDA commissioner.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.
Technology Review points out that a new US presidential science advisor hasn't been selected.
The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.
The Wall Street Journal says President-elect Donald Trump's pick to lead the Department of Health and Human Services traded medical company stock while supporting legislation affecting such firms.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.